In Conversation With… Albert Whangbo, PhD
“Steroids are cheap and effective in the short term. Convincing payers that steroid-sparing therapies are worth the upfront cost is still a practical challenge.” Albert Whangbo, PhD, leads the global ...
Academic Uptake of Steritas STOX Suite Expands Across Trials and Institutions
Academic institutions worldwide are increasingly adopting the clinical outcome assessments (COA) of steroid-toxicity that make up the STOX® Suite from Steritas. To date, 26 academic licenses are in ...
In Conversation With… Lori McLeod, PhD
“Behind every data point is a patient story - and it’s the responsibility of healthcare researchers and practitioners to listen, measure, and respond.” As Vice President of Patient-Centered Outcomes ...
Designing Trials That Capture What Matters: Efficacy, Safety, and Steroid-toxicity
Despite decades of widespread use, steroids are facing a growing backlash. Leading researchers and sponsors are aligning on a new imperative: quantify the harm. A flurry of guidance, tools, and ...
In Conversation With… Professor Ailsa Hart
“We have to make the case that avoiding steroids isn’t just about following guidelines - it’s about protecting the long-term health of our patients.” Steroids remain a cornerstone of inflammatory ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
